Physician profile
Caroline W Silver
NPI 1417940958
$3,295.96
in general payments reported to CMS, 2019-2025
13 companies · $794 in 2025
The $794 reported for 2025 was more than what 87% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $63.87 · 2021: $214 · 2022: $487 · 2023: $785 · 2024: $596 · 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,175.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $725.22 | 2019-2025 | Clariti Contact Lens, Myday Contact Lens, Misight Contact Lens |
| Bausch & Lomb Americas INC. | $573.11 | 2022-2025 | Infuse, Miebo, Vyzulta |
| Alcon Vision LLC | $558.98 | 2019-2025 | Total30, Precision 1, Eysuvis |
| Johnson & Johnson Vision Care, INC. | $269.06 | 2021-2025 | Acuvue |
| Novartis Pharmaceuticals Corporation | $251.37 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $205.84 | 2021-2025 | Cequa |
| Oyster Point Pharma, INC. | $177.84 | 2022-2023 | Tyrvaya |
| Harrow Eye, LLC | $152.61 | 2024-2025 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $132.39 | 2019-2021 | |
| Astellas Pharma US INC | $125.00 | 2024 | Izervay |
| Shire North American Group INC | $61.45 | 2019 | |
| Kala Pharmaceuticals, INC. | $41.65 | 2021-2022 | |
| Allergan, INC. | $21.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Silver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.